OAG Acquires Infare and Receives New Investment from Vitruvian Partners
28.7.2023 15:37:00 EEST | Business Wire | Press release
OAG, the world’s leading data platform for the global travel industry, has acquired Infare, the leading provider of competitor air travel data, from Ventiga Capital in a deal valuing the combined entity at over US$500m. Together, OAG and Infare have an exciting journey ahead to leverage a truly market-leading end-to-end data platform to serve mission-critical air travel intelligence needs across the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230728627752/en/
With renowned industry heritage, both businesses share a deep passion for quality, accuracy, and customer-centricity. Together, there is a significant opportunity for OAG and Infare to better serve airline partners and the wider travel ecosystem with high-quality data and innovative solutions.
Infare is the partner of choice for airlines demanding the highest quality competitor air travel data source to support their growth. Combining OAG’s existing data solutions with airfare data creates a compelling proposition for customers who can get a broader picture of supply and demand. This enables customers to forecast resource, evaluate travel demand and competition, and build more complex and innovative models to drive revenue and profitable growth.
Through the acquisition, OAG now grows to over 300 employees globally across 10 offices.
Phil Callow, CEO of OAG, commented:
“The increasing dynamism in global travel and technology is fuelling a need for more sophisticated, granular data to understand, manage and unlock growth in air travel. The acquisition of Infare strengthens our ability to deliver consistent and accurate information across the wider supply and demand value chain. Together, we are enabling new and existing customers to thrive and innovate ahead of their counterparts. I am excited to welcome Infare colleagues to the OAG family.”
Nils Gelbjerg-Hansen, CEO of Infare, commented:
“Access to comprehensive and accurate data is paramount for making informed business decisions. Airlines rely on data to gain valuable insights into customer behaviour, market trends, and operational efficiency. Our technology platform, data sets, and intelligence software complement OAG’s and will greatly benefit our customers worldwide. We see this as a unique opportunity to expand our services and introduce new innovative products for our customers, we are excited about the journey ahead together.”
Both management teams will continue in the Group and will retain a shareholding, with fresh backing provided by Vitruvian Partners.
Ben Johnson, a Partner at Vitruvian, commented:
“OAG and Infare are both clear leaders in their respective global markets. The combination creates additional growth opportunities for both teams. Vitruvian is delighted to support this ambitious technology company and renew our relationship with them for the years to come.”
Niclas Gabrán, Managing Partner at Ventiga Capital Partners, commented:
“It has been a pleasure working together with Nils and his team to build Infare into a leading travel data provider through organic growth and acquisitions. Infare’s next chapter as a part of the OAG family will undoubtedly create further growth opportunities both within and outside the air travel sector.”
About OAG
OAG is the leading data platform for the global travel industry, powering the growth and innovation of the air travel ecosystem since 1929. It has the world’s largest network of flight information, covering the whole journey from planning to customer experience. Customers include airlines, airports, travel technology players, aviation service providers, government agencies, financial institutions, and consultancies. Headquartered in the UK, OAG has operations in the USA, Singapore, Japan, China, and Lithuania. For more information, visit: www.oag.com and follow us on Twitter @OAG Aviation.
About Infare
Infare is the leading competitor air travel data provider, empowering airlines to make effective pricing decisions. Infare’s mission is to fuel airline systems with high-quality competitor air travel data delivered daily, multiple times a day or live. Founded in 2000 and headquartered in Copenhagen, Denmark, the company has a global reach and presence worldwide. For more information, visit www.infare.com and follow us on LinkedIn.
About Vitruvian Partners
Vitruvian is an independent growth capital firm headquartered in London with a global presence. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries spanning technology, financial services, healthcare, and business and consumer services. Vitruvian is among the largest pools of capital in Europe supporting innovative and higher growth companies. Vitruvian Funds have backed over 90 companies and have assets under management of €15+ billion. Notable investments to date include global market leaders and innovators in their field such as Skyscanner, Sykes Holiday Cottages, CFC Underwriting, CallCredit, Travel Counsellors, Trustpilot, Farfetch, Just Eat, Wise, and Global-e.
About Ventiga Capital Partners
Ventiga is an entrepreneurial and growth-focused investor partnering with exceptional entrepreneurs and management teams to achieve sustainable, profitable growth and transformational value through active, engaged, and responsible ownership. Ventiga invests in profitable growth companies with superior business expansion potential, primarily in the B2B services space.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230728627752/en/
Contact information
Media Enquiries
pressoffice@oag.com
UK/EMEA /ASPAC
Dom Conolly/ Harvard PR
North America
Chrissy Azevedo
Corporate Ink for OAG
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
